U.S. Markets closed

Neurocrine Biosciences Has Robust Late-Stage Pipeline

Margaret Patrick
Neurocrine Biosciences Has Robust Late-Stage Pipeline

Is Neurocrine Biosciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Opicapone in Parkinson’s DiseaseIn its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug